Hareket Bozuklukları
Özet
Hareket bozuklukları, bazal gangliyonlar ve ilgili nöral ağların işlev bozukluğu sonucu ortaya çıkan, güçsüzlük veya spastisite kaynaklı olmayan nörolojik sendromlardır. Bu bozukluklar, distoni, kore, tremor ve tik gibi anormal istemsiz hareketlerin görüldüğü hiperkinetik grup ile parkinsonizm gibi hareket azlığı ile karakterize hipokinetik grup olmak üzere iki ana sınıfta incelenir. Tedavi süreçleri, altta yatan etiyolojik nedenlerin doğru tanımlanmasına odaklanarak farmakolojik ve destekleyici yöntemlerle hastanın yaşam kalitesini artırmayı hedefler.
Movement disorders are neurological syndromes resulting from the dysfunction of the basal ganglia and related neural networks, not primarily caused by weakness or spasticity. These conditions are categorized into two main groups: the hyperkinetic group, characterized by abnormal involuntary movements such as dystonia, chorea, tremor, and tics, and the hypokinetic group, characterized by reduced movement as seen in parkinsonism. Treatment processes focus on the accurate identification of underlying etiological causes, aiming to improve the patient's quality of life through pharmacological and supportive interventions.
Referanslar
Tekgül H, Yılmaz S. Çocuklarda Hareket Bozuklukları: Sınıflandırma, Fizyopatoloji ve Klinik Gözlemsel Yaklaşım. Aydın K, editör. Çocuklarda Hareket Bozuklukları Özel Sayısı. 1. Baskı. Ankara: Türkiye Klinikleri; 2017. p.73-80.
Taner D, Atasever A, Durgun B. Bazal Ganglionlar. Taner D, editör. Fonksiyonel Nöroanatomi. 20. baskı. Ankara; 2018. p.170-8
Okan M. Çocukluk dönemi hareket bozuklukları. Gökçay E, Sönmez F, Topaloğlu H, Tekgül H, Gürer Y, editörler. Çocuk Nörolojisi. 1. baskı. Ankara; 2006. p.355-70.
Mink JW. The basal ganglia: Focused selection and inhibition of competing motor programs. Prog Neurobiol. 1996;50(4):381-425.
Singer HS, Jankovic J, Mink JW, Gilbert DL. Movement Disorders in Childhood. 2nd ed. Philadelphia, Pa 19103-2899; 2016.
Fahn S, Marsden CD, Calne D. Classification and investigtaion of dystonia. Fahn S, Marsden C, eds. Movement Disorders. 2nd ed. London: Butterworth; 1987. p.332-58.
Badheka R, Barad N, Sankhla C. Pediatric movement disorders. Neurol India. 2018;66(7):59.
Nikkhah A, Karimzadeh P, Taghdiri MM, Nasehi MM, Javadzadeh M, Khari E. Hyperkinetic Movement Disorders in Children: A Brief Review. Iran J Child Neurol. 2019;13(2):7-16
Frucht L, Perez DL, Callahan J, et al. Functional Dystonia: Differentiation From Primary Dystonia and Multidisciplinary Treatments. Front Neurol. 2021;11:605262.
Jinnah HA, Neychev V, Hess EJ. The Anatomical Basis for Dystonia: The Motor Network Model. Tremor Other Hyperkinet Mov. 2017;7:506.
Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord. 2010;25(11):1538-49.
Klein C, Lohmann K, Marras C, Münchau A. Hereditary Dystonia Overview. GeneReviews. Seattle (WA);1993-2021.
Loher TJ, Krauss JK. Dystonia Associated with Pontomesencephalic Lesions. Mov Disord. 2009;24(2):157-67.
Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013;28(7):863-73.
Sanger T, Mink J. Movement Disorders. Swaiman K, Ashwal S, Ferriero D, Schor N, eds. Swaiman’s Pediatric Neurology: Principles and Practice. 5th ed. China: Elsevier Saunders; 2012. p.965-98.
Tabbal SD. Childhood Dystonias. Curr Treat Options Neurol. 2015;17(3):1-25.
Lee WW, Jeon BS. Clinical Spectrum of Dopa-Responsive Dystonia and Related Disorders. Curr Neurol Neurosci Rep. 2014;14(7):461
Dong HY, Feng JY, Yue XJ, Shan L, Jia FY. Dopa-responsive dystonia caused by tyrosine hydroxylase deficiency: Three cases report and literature review. Medicine (Baltimore). 2020;99(33):217-53.
Asmus F, Salih F, Hjermind LE, et al. Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol. 2005;58(5):792-97.
Kinugawa K, Vidailhet M, Clot F, Apartis E, Grabli D, Roze E. Myoclonus-dystonia: An update. Mov Disord. 2009;24(4):479-89.
Per H, Bayram AK. Çocukluk Çağında Distoni. Aydın K, editör. Çocuklarda Hareket Bozuklukları Özel Sayısı. 1. Baskı. Ankara: Türkiye Klinikleri; 2017. p.145-54.
Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5(10):864-72.
Erol İ. Çocuk ve Ergenlerde Kore. Aydın K, editör. Çocuklarda Hareket Bozuklukları Özel Sayısı. 1. Baskı. Ankara: Türkiye Klinikleri; 2017. p.135-44.
Macerollo A, Martino D. What is new in tics, dystonia and chorea? Clin Med (Lond). 2016;16(4):383-9.
de Gusmao CM, Waugh JL. Inherited and Acquired Choreas. Semin Pediatr Neurol. 2018;25:42-53.
Yilmaz S, Mink JW. Treatment of Chorea in Childhood. Pediatr Neurol. 2020;102:10-19.
Gilbert DL. Acute and Chronic Chorea in Childhood. Semin Pediatr Neurol. 2009;16(2):71-76.
Asmus F, Horber V, Pohlenz J, et al. A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa. Neurology. 2005;64(11):1952-4.
Inzelberg R, Weinberger M, Gak E. Benign hereditary chorea: An update. Park Relat Disord. 2011;17(5):301-7.
Dayalu P, Albin RL. Huntington Disease: Pathogenesis and Treatment. Neurol Clin. 2015;33(1):101-14.
Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin Is a Neuronal Target of Autoantibodies in Sydenham’s Chorea. J Immunol. 2007;178(11):7412-21.
Paz JA, Silva CAA, Marques-Dias MJ. Randomized Double-Blind Study With Prednisone in Sydenham’s Chorea. Pediatr Neurol. 2006;34(4):264-9.
Walker K, Brink A, Lawrenson J, Mathiassen W, Wilmshurst JM. Treatment of Sydenham chorea with intravenous immunoglobulin. J Child Neurol. 2012;27(2):147-55.
Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord. 2006;21(11):1966-72.
Demiroren K, Yavuz H, Cam L, Oran B, Karaaslan S, Demiroren S. Sydenham’s chorea: A clinical follow-up of 65 patients. J Child Neurol. 2007;22(5):550-4.
Roze E, Lang AE, Vidailhet M. Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. Curr Opin Neurol. 2018;31(4):484-90.
Caviness JN. Chapter 32 The clinical neurophysiology of myoclonus. Handbook of Clinical Neurophysiology. 2003. p.521-48.
Cassim F, Houdayer E. Neurophysiology of myoclonus. Neurophysiol Clin. 2006;36(5-6):281-91.
Haspolat Ş. Miyoklonus. Aydın K, editör. Çocuklarda Hareket Bozuklukları Özel Sayısı. 1. Baskı. Ankara: Türkiye Klinikleri; 2017. p.155-9.
Hayashi T, Ichiyama T, Nishikawa M, Furukawa S. Carbamazepine and myoclonus in SSPE subacute sclerosing panencephalitis. Pediatr Neurol. 1996;14(4):346.
Levy A, Chen R, BChir MB. Myoclonus: Pathophysiology and Treatment Options. Curr Treat Options Neurol. 2016;18(5):2-17
Keller S, Dure LS. Tremor in Childhood. Semin Pediatr Neurol. 2009;16(2):60-70.
Ünay B. Tremor. Aydın K, editör. Çocuklarda Hareket Bozuklukları Özel Sayısı. 1. Baskı. Ankara: Türkiye Klinikleri; 2017. p.130-4.
Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson’s disease. Park Relat Disord. 2007;13(2):67-76.
Stefansson H, Steinberg S, Petursson H, et al. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat Genet. 2009;41(3):277-9.
Elble RJ. The Essential Tremor Rating Assessment Scale. J Neurol Neuromed. 2016;1(4):34-38.
Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor: A double-blind, placebo-controlled trial. Neurology. 2006;66(5):672-7.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 2013.
Diniz JB, Rosario-Campos MC, Hounie AG, et al. Chronic tics and Tourette syndrome in patients with obsessive-compulsive disorder. J Psychiatr Res. 2006;40(6):487-93.
Roessner V, Becker A, Banaschewski T, Rothenberger A. Psychopathological profile in children with chronic tic disorder and co-existing ADHD: Additive effects. J Abnorm Child Psychol. 2007;35(1):79-85.
Rounds G, Mills S, Hedderly T. A Guide to Childhood Motor Stereotypies, Tic Disorders and the Tourette Spectrum for the Primary Care Practitioner. Ulster Med J. 2014;83(1):22-30.
Singer HS, Minzer K. Neurobiology of Tourette’s syndrome: Concepts of neuroanatomic localization and neurochemical abnormalities. Brain and Development. 2003;25(1):70-84.
Kamaşak T, Cansu A. Tik Bozuklukları. Aydın K, editör. Çocuklarda Hareket Bozuklukları Özel Sayısı. 1. Baskı. Ankara: Türkiye Klinikleri; 2017. p.121-9.
Vincent DA. Botulinum Toxin in the Management of Laryngeal Tics. J Voice. 2008;22(2):251-6.
Welter ML, Mallet L, Houeto JL, et al. Internal pallidal and thalamic stimulation in patients with Tourette syndrome. Arch Neurol. 2008;65(7):952-7.
Hymas N, Lees A, Bolton D, Epps K, Head D. The neurology of obsessional slowness. Brain. 1991;114(5):2203-33.
Miller JM, Singer HS, Bridges DD, Waranch HR. Behavioral therapy for treatment of stereotypic movements in nonautistic children. J Child Neurol. 2006;21(2):119-25.
Carrasco M, Volkmar FR, Bloch MH. Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: Evidence of publication bias. Pediatrics. 2012;129(5):1301-10.
Bhatia KP. Paroxysmal dyskinesias. Mov Disord. 2011;26(6):1157-65.
Demirkiran M, Jankovic J. Paroxysmal dyskinesias: Clinical features and classification. Ann Neurol. 1995;38(4):571-9.
Bruno MK, Hallett M, Gwinn-Hardy K, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: New diagnostic criteria. Neurology. 2004;63(12):2280-7.
Gardiner AR, Jaffer F, Dale RC, et al. The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain. 2015;138(12):3567-80
Uçar HK, Aydın K. Paroksismal Diskineziler. Aydın K, editör. Çocuklarda Hareket Bozuklukları Özel Sayısı. 1. Baskı. Ankara: Türkiye Klinikleri; 2017. p.96-103.
Bruno MK, Lee HY, Auburger GWJ, et al. Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology. 2007;68(21):1782-9.
Garone G, Capuano A, Travaglini L, et al. Clinical and genetic overview of paroxysmal movement disorders and episodic ataxias. Int J Mol Sci. 2020;21(10):3603.
Agostinelli S, Traverso M, Accorsi P, et al. Early-onset absence epilepsy: SLC2A1 gene analysis and treatment evolution. Eur J Neurol. 2013;20(5):856-9.
Kluge A, Kettner B, Zschenderlein R, et al. Changes in perfusion pattern using ECD-SPECT indicate frontal lobe and cerebellar involvement in exercise-induced paroxysmal dystonia. Mov Disord. 1998;13(1):125-34.
Eltahawy HA, Saint-Cyr J, Giladi N, et al. Primary Dystonia is More Responsive than Secondary Dystonia to Pallidal Interventions: Outcome after Pallidotomy or Pallidal Deep Brain Stimulation. Neurosurgery. 2004;54(3):613-21.
Jankovic J, Tan EK. Parkinson's disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795-808.
Kara B. Çocuklarda Hipokinetik Hareket Bozuklukları ve Parkinsonizm. Aydın K, editör. Çocuklarda Hareket Bozuklukları Özel Sayısı. 1. Baskı. Ankara: Türkiye Klinikleri; 2017. p.104-11.
Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3:1-21.
Niemann N, Jankovic J. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Park Relat Disord. 2019;67:74-89.
Pearl PL, Taylor JL, Trzcinski S, Sokohl A. The pediatric neurotransmitter disorders. J Child Neurol. 2007;22(5):606-16.
Mercimek-Mahmutoglu S, Sidky S, Hyland K, et al. Prevalence of inherited neurotransmitter disorders in patients with movement disorders and epilepsy: a retrospective cohort study. Orphanet J Rare Dis. 2015;10:12.
Jaeken J, Jakobs C, Clayton PT, Wevers RA. Disorders of neurotransmission. Inborn Metabolic Diseases: Diagnosis and Treatment. Springer Berlin Heidelberg; 2006. p.359-72.
Ng J, Zhen J, Meyer E, et al. Dopamine transporter deficiency syndrome: Phenotypic spectrum from infancy to adulthood. Brain. 2014;137(4):1107-19.
Doummar D, Moussa F, Nougues MC, et al. Monoamine neurotransmitters and movement disorders in children and adults. Rev Neurol (Paris). 2018;174(9):581-8.
Reale C, Panteghini C, Carecchio M, Garavaglia B. The relevance of gene panels in movement disorders diagnosis: A lab perspective. Eur J Paediatr Neurol. 2018;22(2):285-91.
